Literature DB >> 10591862

Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice.

M P Epping-Jordan1, M R Picciotto, J P Changeux, E M Pich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10591862     DOI： 10.1007/s002130051135

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  34 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

3.  Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  J Med Chem       Date:  2010-10-27       Impact factor: 7.446

4.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

Review 5.  Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.

Authors:  Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-10-21       Impact factor: 4.530

6.  Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001.

Authors:  Andrea Cippitelli; Gloria Brunori; Kelly A Gaiolini; Nurulain T Zaveri; Lawrence Toll
Journal:  Neuropharmacology       Date:  2015-02-14       Impact factor: 5.250

7.  Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.

Authors:  Megan J Shram; Eric C K Siu; Zhaoxia Li; Rachel F Tyndale; Anh D Lê
Journal:  Psychopharmacology (Berl)       Date:  2008-04-03       Impact factor: 4.530

8.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

Review 9.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 10.  Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans.

Authors:  Agnes J Jasinska; Todd Zorick; Arthur L Brody; Elliot A Stein
Journal:  Neuropharmacology       Date:  2013-03-06       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.